Real‐Life Outcome in Multiple Sclerosis in the Czech Republic
G Kobelt, L Jönsson, M Pavelcova… - Multiple Sclerosis …, 2019 - Wiley Online Library
Background. Cohort studies and registries provide opportunities to estimate long‐term
outcome in multiple sclerosis. Objectives. To describe changes in disability (EDSS), relapse …
outcome in multiple sclerosis. Objectives. To describe changes in disability (EDSS), relapse …
New insights into the burden and costs of multiple sclerosis in Europe
G Kobelt, A Thompson, J Berg… - Multiple Sclerosis …, 2017 - journals.sagepub.com
Background: The current focus in multiple sclerosis (MS) is on early diagnosis and drug
intervention, with a view to modifying disease progression. Consequently, healthcare costs …
intervention, with a view to modifying disease progression. Consequently, healthcare costs …
New insights into the burden and costs of multiple sclerosis in Europe: results for Switzerland
P Calabrese, G Kobelt, J Berg, D Capsa… - Multiple Sclerosis …, 2017 - journals.sagepub.com
Introduction: To estimate the value of interventions in multiple sclerosis (MS)–where lifetime
costs and outcomes cannot be observed–outcome data have to be combined with costs …
costs and outcomes cannot be observed–outcome data have to be combined with costs …
New insights into the burden and costs of multiple sclerosis in Europe: results for Austria
T Berger, G Kobelt, J Berg, D Capsa… - Multiple Sclerosis …, 2017 - journals.sagepub.com
Introduction: In order to estimate the value of interventions in multiple sclerosis (MS)–where
lifetime costs and outcomes cannot be observed–outcome data have to be combined with …
lifetime costs and outcomes cannot be observed–outcome data have to be combined with …
New insights into the burden and costs of multiple sclerosis in Europe: results for the Netherlands
B Uitdehaag, G Kobelt, J Berg, D Capsa… - Multiple Sclerosis …, 2017 - journals.sagepub.com
Introduction: To estimate the value of interventions in multiple sclerosis (MS)–where lifetime
costs and outcomes cannot be observed–outcome data have to be combined with costs …
costs and outcomes cannot be observed–outcome data have to be combined with costs …
New insights into the burden and costs of multiple sclerosis in Europe: Results of the Czech Republic
E Havrdova, G Kobelt, J Berg, D Capsa… - Multiple Sclerosis …, 2017 - journals.sagepub.com
Introduction: In order to estimate the value of interventions in multiple sclerosis (MS)–where
lifetime costs and outcomes cannot be observed–outcome data have to be combined with …
lifetime costs and outcomes cannot be observed–outcome data have to be combined with …
Burden of illness in multiple sclerosis (DEFENSE) study: the costs and quality-of-life of Finnish patients with multiple sclerosis
J Ruutiainen, AM Viita, J Hahl, J Sundell… - Journal of medical …, 2016 - Taylor & Francis
Objective: Although multiple sclerosis (MS) is one of the most common causes of non-
traumatic disability among young adults, no published data on its economic and health …
traumatic disability among young adults, no published data on its economic and health …
New insights into the burden and costs of multiple sclerosis in Europe: Results for Belgium
B Dubois, G Kobelt, J Berg, D Capsa… - Multiple Sclerosis …, 2017 - journals.sagepub.com
Introduction: In order to estimate the value of interventions in multiple sclerosis (MS)–where
lifetime costs and outcomes cannot be observed–outcome data have to be combined with …
lifetime costs and outcomes cannot be observed–outcome data have to be combined with …
New insights into the burden and costs of multiple sclerosis in Europe: Results for Denmark
PV Rasmussen, G Kobelt, J Berg… - Multiple Sclerosis …, 2017 - journals.sagepub.com
Background: To estimate the value of treatments in multiple sclerosis (MS)–where lifetime
costs and outcomes cannot be observed–outcome data have to be combined with cost data …
costs and outcomes cannot be observed–outcome data have to be combined with cost data …
New insights into the burden and costs of multiple sclerosis in Europe: Results for Poland
K Selmaj, G Kobelt, J Berg, E Orlewska… - Multiple Sclerosis …, 2017 - journals.sagepub.com
Background: In order to estimate the value of interventions in multiple sclerosis (MS)–where
lifetime costs and outcomes cannot be observed–outcome data have to be combined with …
lifetime costs and outcomes cannot be observed–outcome data have to be combined with …